SAFETY AND EFFECTIVENESS OF HIGH DOSE/LONG DURATION ABLC THERAPY

Hooshmand-Rad R1, Reed MD2, Chu A1, Gotz V1, Morris JA1, Batty S3, Dominguez EA4

Author address: 

1ProSanos Corporation, La Jolla, USA; 2 School of Medicine, Department of Pediatrics, Case Western Reserve University, Cleveland, USA; 3ENZON Pharmaceuticals, Bridgewater, USA; 4Department of Medicine, Section of Infectious Diseases, University of

Abstract: 

Purpose To determine the safety of high dose/long duration (HD/LD) Amphotericin B Lipid Complex (ABLC) treatment of fungal infections in comparison to low dose/short duration (LD/SD) ABLC therapy. Methods A large multi center patient registry, the Collaborative Exchange of Antifungal Research (CLEAR) was used to retrospectively review patients treated with HD/LD (>5mg/kg/d for >12d, median dose of 5.6 mg/kg/d, range of 5 10 mg/kg/d for a median duration of 21 days, range of 13 - 182 days) and LD/SD (5mg/kg/d for >12 days does not appear to compromise patient renal function even in patients who receive concomitant nephrotoxic medication(s).
2004

abstract No: 

none

Full conference title: 

14th Annual Focus on Fungal Infections
    • FFI 14th (2004)